Literature DB >> 19815403

The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.

Jeffrey J Swigris1, Kevin K Brown, Juergen Behr, Roland M du Bois, Talmadge E King, Ganesh Raghu, Frederick S Wamboldt.   

Abstract

RATIONALE: Health-related quality of life (HRQL) is an important outcome in drug trials. Little is known about how the Short Form-36 (SF-36) and Saint George's Respiratory Questionnaire (SGRQ) perform in idiopathic pulmonary fibrosis (IPF).
OBJECTIVES: To examine the validity of the SF-36 and SGRQ and to determine scores from each that would constitute a minimum important difference (MID).
METHODS: We analyzed data from a recently completed trial that enrolled subjects with well-defined IPF who completed the SF-36, SGRQ, and Baseline/Transition Dyspnea Index at baseline and six months. We compared mean changes in HRQL scores between groups of subjects whose disease severity changed over six months according to clinical anchors (FVC, DLCO, and dyspnea). We estimated the MID for each domain by using both anchor- and distribution-based approaches. MAIN
RESULTS: Results supported the validity of the SF-36 and SGRQ for use in longitudinal studies. Mean changes in domain scores differed significantly between subjects whose clinical status improved and those whose clinical status declined according to the anchors. MID estimates for the SF-36 ranged from 2-4 points and from 5-8 points for the SGRQ.
CONCLUSION: In IPF, the SF-36 and SGRQ possess reasonable validity for differentiating subjects whose disease severity changes over time. More studies are needed to continue the validation process, to refine estimates of the MIDs for the SF-36 or SGRQ, and to determine if a disease-specific instrument will perform better than either of these.

Entities:  

Mesh:

Year:  2009        PMID: 19815403      PMCID: PMC2856332          DOI: 10.1016/j.rmed.2009.09.006

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  21 in total

Review 1.  American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

Review 2.  Health status measurement in chronic obstructive pulmonary disease.

Authors:  P W Jones
Journal:  Thorax       Date:  2001-11       Impact factor: 9.139

3.  St. George's Respiratory Questionnaire: MCID.

Authors:  Paul W Jones
Journal:  COPD       Date:  2005-03       Impact factor: 2.409

4.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

5.  Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis.

Authors:  M Kosinski; S Z Zhao; S Dedhiya; J T Osterhaus; J E Ware
Journal:  Arthritis Rheum       Date:  2000-07

Review 6.  Health-related quality of life among patients with idiopathic pulmonary fibrosis.

Authors:  Jeffrey J Swigris; Michael K Gould; Sandra R Wilson
Journal:  Chest       Date:  2005-01       Impact factor: 9.410

7.  The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes.

Authors:  D A Mahler; D H Weinberg; C K Wells; A R Feinstein
Journal:  Chest       Date:  1984-06       Impact factor: 9.410

8.  Minimal important difference of the transition dyspnoea index in a multinational clinical trial.

Authors:  T J Witek; D A Mahler
Journal:  Eur Respir J       Date:  2003-02       Impact factor: 16.671

9.  Health-related quality of life in patients with idiopathic pulmonary fibrosis--cross-sectional and longitudinal study.

Authors:  Hiromi Tomioka; Kazufumi Imanaka; Kimio Hashimoto; Hironobu Iwasaki
Journal:  Intern Med       Date:  2007-09-14       Impact factor: 1.271

10.  BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.

Authors:  Talmadge E King; Jürgen Behr; Kevin K Brown; Roland M du Bois; Lisa Lancaster; Joao A de Andrade; Gerd Stähler; Isabelle Leconte; Sébastien Roux; Ganesh Raghu
Journal:  Am J Respir Crit Care Med       Date:  2007-09-27       Impact factor: 21.405

View more
  81 in total

1.  The prognostic value of pre-diagnosis health-related quality of life on survival: a prospective cohort study of older Americans with lung cancer.

Authors:  Laura C Pinheiro; Timothy M Zagar; Bryce B Reeve
Journal:  Qual Life Res       Date:  2017-02-14       Impact factor: 4.147

2.  A comparison of health-related quality of life in idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis.

Authors:  Molly Lubin; Hubert Chen; Brett Elicker; Kirk D Jones; Harold R Collard; Joyce S Lee
Journal:  Chest       Date:  2014-06       Impact factor: 9.410

3.  Patient-reported outcomes in idiopathic pulmonary fibrosis research.

Authors:  Jeffrey J Swigris; Diane Fairclough
Journal:  Chest       Date:  2012-08       Impact factor: 9.410

4.  A dance intervention for cancer survivors and their partners (RHYTHM).

Authors:  Maria Pisu; Wendy Demark-Wahnefried; Kelly M Kenzik; Robert A Oster; Chee Paul Lin; Sharon Manne; Ronald Alvarez; Michelle Y Martin
Journal:  J Cancer Surviv       Date:  2017-01-09       Impact factor: 4.442

5.  Understanding the determinants of health-related quality of life in rheumatoid arthritis-associated interstitial lung disease.

Authors:  Jake G Natalini; Jeff J Swigris; Julie Morisset; Brett M Elicker; Kirk D Jones; Aryeh Fischer; Harold R Collard; Joyce S Lee
Journal:  Respir Med       Date:  2017-04-05       Impact factor: 3.415

6.  The UCSD shortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis.

Authors:  Jeffrey J Swigris; Meilan Han; Rekha Vij; Imre Noth; Eric L Eisenstein; Kevin J Anstrom; Kevin K Brown; Diane Fairclough
Journal:  Respir Med       Date:  2012-07-15       Impact factor: 3.415

7.  A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis.

Authors:  David A Zisman; Marvin Schwarz; Kevin J Anstrom; Harold R Collard; Kevin R Flaherty; Gary W Hunninghake
Journal:  N Engl J Med       Date:  2010-05-18       Impact factor: 91.245

8.  Pre-diagnosis health-related quality of life and survival in older women with endometrial cancer.

Authors:  Amy K Klapheke; Theresa H M Keegan; Rachel Ruskin; Rosemary D Cress
Journal:  Support Care Cancer       Date:  2020-02-01       Impact factor: 3.603

9.  St. George's Respiratory Questionnaire has longitudinal construct validity in lymphangioleiomyomatosis.

Authors:  Jeffrey J Swigris; Hye-Seung Lee; Marsha Cohen; Yoshikazu Inoue; Joel Moss; Lianne G Singer; Lisa R Young; Francis X McCormack
Journal:  Chest       Date:  2013-06       Impact factor: 9.410

Review 10.  New perspectives on management of idiopathic pulmonary fibrosis.

Authors:  Silvia Puglisi; Sebastiano Emanuele Torrisi; Virginia Vindigni; Riccardo Giuliano; Stefano Palmucci; Massimiliano Mulè; Carlo Vancheri
Journal:  Ther Adv Chronic Dis       Date:  2016-02-01       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.